Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3m Syndrome 3 C3280146
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3M Syndrome 3 for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3m Syndrome 3 C3280146
A genetic condition causing intrauterine growth restriction and postnatal short stature with distinctive facial features. Treatment focuses on growth monitoring and supportive measures.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3m Syndrome 3 C3280146
0-0
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3m Syndrome 3 C3280146
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3m Syndrome 3 C3280146
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3m Syndrome 3 C3280146
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3m Syndrome 3 C3280146
musculoskeletal
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3m Syndrome 3 C3280146
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3m-syndrome-3-C3280146 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3m Syndrome 3 C3280146 | Discriminating power |
|---|---|---|---|
| Neurologic features | Developmental delay, seizures, and movement difficulty are described. | Neurologic disease is not established by the supplied description. | High |
| Growth pattern | Growth restriction is not the defining feature in the source data. | Intrauterine growth restriction and postnatal short stature are characteristic. | High |
| Facial appearance | Distinctive facial features are not established here. | Distinctive facial features are described. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Early neurologic presentation
Seizures, developmental delay, or movement difficulty suggest a serine-related metabolic disorder.
Moderate
Suspected serine deficiency
The condition impairs serine production and primarily affects the nervous system.
High
Metabolic rather than skeletal pattern
Source classification is metabolic, not musculoskeletal.
Moderate
Choose 3m Syndrome 3 C3280146 when
Prenatal growth restriction
Intrauterine growth restriction is a stated feature of 3M syndrome 3.
High
Persistent short stature
Postnatal short stature with supportive growth monitoring fits the description.
Moderate
Characteristic facial findings
Distinctive facial features support consideration of this genetic condition.
Moderate
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3m Syndrome 3 C3280146 | Interpretation |
|---|---|---|---|
| Amino acid assessment | May support impaired serine production; exact cutoffs are not supplied. | No characteristic amino acid abnormality is established here. | An abnormal result is not itself a diagnosis and needs specialist review. |
| Genetic testing | May identify a cause of the metabolic disorder when clinically indicated. | May support the genetic diagnosis of 3M syndrome 3. | Gene selection and interpretation require a genetics clinician. |
| Growth assessment | Not the primary discriminator in the supplied data. | Documents intrauterine restriction and postnatal short stature. | Growth findings should be interpreted with clinical and genetic context. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- A severe chronic neurologic course is described, but individual outcome is not established.
- Factors
- Seizure control, developmental support, and response to serine supplementation may matter.
3m Syndrome 3 C3280146
- Outcome
- A moderate chronic course centered on short stature is described.
- Factors
- Growth pattern and need for supportive care influence management.
Time frame: Both are chronic; precise timelines and survival data are not supplied.
Prognosis should be individualized because source evidence is limited.
Complications comparison
| Complication | Presentation |
|---|---|
| Seizures | Seizures are a described neurologic feature. Seizure risk is not established by the source. Anticonvulsant use, if needed, should be individualized. |
| Developmental impairment | Developmental delay is described. Developmental outcome is not specified here. Do not infer cognitive prognosis from these sparse data. |
| Short stature | Not established as a defining complication. Postnatal short stature is characteristic. Management emphasizes monitoring and supportive care. |
Patient education highlights
- HighDifferent conditions
These disorders affect different systems and should not be treated as interchangeable.
- HighSpecialist care
Metabolic, neurologic, or genetics clinicians should guide testing and treatment decisions.
- MediumSupportive management
Serine supplementation or anticonvulsants may be used for the metabolic disorder; growth support is emphasized for 3M syndrome 3.